GET DAILY SIGNALSEdgewise Therapeutics (EWTX) Q3 Turnaround Highlights Cardiovascular Pivot After +17.9% Surge
Key Takeaways
- Edgewise reported third-quarter 2026 net income of $1.166 billion, or $9.65 per diluted share, swinging from a net loss of $40.7 million a year earlier.
- The turnaround was driven by a one-time $1.348 billion gain from the completed sale of its sevasemten program and muscular dystrophy business to Servier.
- Beneath the headline, the company remains unprofitable, posting a loss from operations of $46.1 million, roughly flat versus $46.9 million in the prior-year quarter.
- Cash, cash equivalents and marketable securities climbed to approximately $1.74 billion, sharply higher than $530.1 million at the end of 2025.
- Edgewise is now a cardiovascular-focused biotech, with a Phase 3 trial of its lead candidate EDG-7500 expected to begin by the end of 2026.
- For more detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
- Explore Trending AI Robots to discover automated strategies and trading ideas across the market.
Why This Quarter Matters
This quarter marks a real turning point for Edgewise Therapeutics (EWTX). In July 2026 the company closed the sale of sevasemten and its muscular dystrophy assets to Servier for roughly $1.396 billion in upfront cash. The deal shifts the profile from a cash-burning clinical developer to a well-funded cardiovascular player. I’m watching closely to see how the one-time gain stacks up against continuing operating losses and whether the stronger balance sheet reduces risk around the two lead programs, EDG-7500 and EDG-15400. For a company without product revenue, the ability to fund late-stage trials internally rather than through dilution stands out as the key takeaway here.
The Numbers Behind the Results
Edgewise Therapeutics (EWTX) posted third-quarter 2026 net income of $1,166.2 million, or $10.71 per basic share and $9.65 per diluted share, versus a net loss of $40.7 million, or $0.39 per share, in the same quarter of 2025. Almost all of the swing came from the $1.348 billion gain on the Servier transaction, offset in part by $155.3 million in related tax expense.
Strip out that gain and the core business stayed in the red. Loss from operations totaled $46.1 million, essentially unchanged from $46.9 million a year earlier. R&D spending fell to $31.6 million from $37.5 million as sevasemten costs dropped after the sale, though spending on EDG-7500 rose. G&A expenses increased to $14.6 million from $9.4 million due to higher personnel and professional fees. No product revenue was recorded. Cash, cash equivalents and marketable securities reached about $1,743.9 million at September 30, 2026, up sharply from $530.1 million at the end of 2025. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Lingering Skepticism
Shares of Edgewise Therapeutics (EWTX) jumped 17.9% to a record high on the June 2026 announcement of the Servier deal, and the stock has posted solid year-to-date gains. The third-quarter filing itself brought few surprises because the gain had already been disclosed. Attention has therefore moved to execution on the cardiovascular pipeline. Short interest still sits near 10% to 11% of shares outstanding, showing that a noticeable slice of the market remains cautious, even as consensus price targets sit well above current levels. This combination of momentum and doubt makes upcoming clinical readouts especially important.
What I’m Watching Next
The clearest near-term catalyst is the planned start of a Phase 3 study for EDG-7500, an oral cardiac sarcomere modulator aimed at hypertrophic cardiomyopathy. Management expects the trial to begin by year-end 2026 after encouraging 12-week Phase 2 data. At the same time, enrollment is under way in the Phase 2 EQUINOX-HFpEF trial of EDG-15400 for heart failure with preserved ejection fraction; the first patient was dosed in the third quarter. Operating losses are expected to persist and R&D outlays should rise as trials advance, but the roughly $1.74 billion cash position gives substantial runway. Management has indicated the funds will support planned activities well beyond the next twelve months and fully cover EDG-7500 development through a potential approval. Up to $1.1 billion in future milestone payments from Servier could provide additional upside, though those remain contingent on development and commercial success.
Enhancing My Research with Tickeron
I regularly turn to Tickeron’s AI Screener when evaluating names like this one. The tool lets me quickly filter for technical patterns, fundamentals, and volatility metrics across thousands of stocks, helping surface comparable setups and confirm where Edgewise Therapeutics (EWTX) stands relative to peers. It has become a practical part of my workflow for earnings-driven ideas.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EWTX sees MACD Histogram crosses below signal line
EWTX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 43 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EWTX as a result. In 86 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EWTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for EWTX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EWTX's RSI Indicator exited the oversold zone, 20 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where EWTX advanced for three days, in 243 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
EWTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.421) is normal, around the industry mean (2.904). P/E Ratio (-21.011) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. EWTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 55 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement